JP2023517536A5 - - Google Patents
Info
- Publication number
- JP2023517536A5 JP2023517536A5 JP2022552946A JP2022552946A JP2023517536A5 JP 2023517536 A5 JP2023517536 A5 JP 2023517536A5 JP 2022552946 A JP2022552946 A JP 2022552946A JP 2022552946 A JP2022552946 A JP 2022552946A JP 2023517536 A5 JP2023517536 A5 JP 2023517536A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- administered
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152.5 | 2020-03-02 | ||
| EP20382152 | 2020-03-02 | ||
| EP20382192.1 | 2020-03-13 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382266.3 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382339.8 | 2020-04-27 | ||
| EP20382816.5 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP20382815.7 | 2020-09-16 | ||
| EP20382815 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| EP21382059.0 | 2021-01-25 | ||
| PCT/EP2021/055187 WO2021175857A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517536A JP2023517536A (ja) | 2023-04-26 |
| JP2023517536A5 true JP2023517536A5 (https=) | 2024-03-12 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552946A Pending JP2023517536A (ja) | 2020-03-02 | 2021-03-02 | 炎症状態に使用するための化合物 |
| JP2022552937A Pending JP2023517535A (ja) | 2020-03-02 | 2021-03-02 | ウイルス感染に使用するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552937A Pending JP2023517535A (ja) | 2020-03-02 | 2021-03-02 | ウイルス感染に使用するための化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159594A1 (https=) |
| EP (2) | EP4114433A2 (https=) |
| JP (2) | JP2023517536A (https=) |
| KR (2) | KR20220151643A (https=) |
| CN (2) | CN115461067A (https=) |
| AU (2) | AU2021232535A1 (https=) |
| BR (2) | BR112022016604A2 (https=) |
| CA (2) | CA3169540A1 (https=) |
| CL (2) | CL2022002396A1 (https=) |
| CO (2) | CO2022014093A2 (https=) |
| IL (2) | IL296069A (https=) |
| MX (2) | MX2022010926A (https=) |
| PE (2) | PE20230606A1 (https=) |
| PY (2) | PY2117301A (https=) |
| TW (2) | TWI908772B (https=) |
| UY (2) | UY39109A (https=) |
| WO (2) | WO2021175831A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230158102A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in the treatment of coronavirus infection |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
| AU2021231521A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | PLD for use in combination in the treatment of coronavirus |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| WO1999052515A2 (de) * | 1998-04-14 | 1999-10-21 | Hassan Jomaa | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen |
| CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| DK1347743T3 (da) * | 2000-12-07 | 2006-07-03 | Univ Utrecht Holding Bv | Præparat til behandling af inflammatoriske lidelser |
| EP1596823A2 (en) * | 2003-02-21 | 2005-11-23 | Sun Pharmaceuticals Industries Ltd. | A stable ophthalmic composition |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| WO2007101235A2 (en) * | 2006-02-28 | 2007-09-07 | Pharma Mar, S.A. | Improved antitumoral treatments |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| BR112012014624A8 (pt) * | 2009-12-15 | 2017-12-26 | Novartis Ag | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US11771739B2 (en) * | 2017-06-16 | 2023-10-03 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
-
2021
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517536A5 (https=) | ||
| Mauss et al. | A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance | |
| JP2023517535A5 (https=) | ||
| JP2011522862A (ja) | テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法 | |
| Abrams | How to use nitrates | |
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| RU2012137097A (ru) | Способ и средство активации irf-3 для лечения и профилактики заболеваний | |
| Kichloo et al. | Emerging therapeutics in the management of COVID-19 | |
| JP2021004249A5 (https=) | ||
| JP2023521744A5 (https=) | ||
| TW202132269A (zh) | 登革熱疾病及治療和預防 | |
| CN106983750A (zh) | 孟鲁司特钠在抑制寨卡病毒、登革病毒及黄热病病毒感染中的应用 | |
| Afaghi et al. | Therapeutic options and critical care strategies in covid-19 patients; where do we stand in this battle? | |
| CN102600129A (zh) | 穿心莲内酯c15位取代衍生物在制备抗丙型肝炎药物中的应用 | |
| JP2023517295A5 (https=) | ||
| Deterding et al. | 1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY–A RANDOMIZED CONTROLLED TRIAL | |
| US20240350659A1 (en) | Compositions and methods for bimodal anti-viral combination therapy | |
| PH12014000275A1 (en) | Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids | |
| JP2023535710A (ja) | ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ | |
| EP4149475A1 (en) | Compositions and methods for treating lung injuries associated with viral infections | |
| CN106562970A (zh) | Gs‑9620的用途 | |
| Alavian | Optimal therapy for hepatitis C | |
| Bahk et al. | Even low-dose treatment of venlafaxine may provoke recurrence of hypertension in an Asian patient? | |
| Wong et al. | Single and combined anti-COVID-19 drugs among hospitalised patients: abridged secondary | |
| Hemmati et al. | Off-label Use of Medicines in COVID-19: A Lesson For Future |